Perspective Therapeutics, Inc. CATX
0.88 USD -0.16 (-15.38%)
At closeNov 3, 2026, 7:38 PM EST
0.94 +0.06 +6.76%
After hours · Nov 3, 7:38 PM ET
0.8759 Day range 1.07
0.88 52-week range 5.65
- YTD
- -68.00%
- 1 year
- -66.15%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 16.15 +1735.2% upside
Now 0.88
- Target (low)
- 6.00
- Target (mean)
- 16.15
- Target (high)
- 21.00
Ratings (0m) 10 9 buy · 1 hold · 0 sell
- Strong buy1
- Buy8
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 10
- 1 month ago 10
- 2 months ago 10
- 3 months ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.25994 | -0.27983 – -0.24 | 0.00 | 0.0% | 257.76K | +105.3% | 3 |
| Next quarter | -0.3003 | -0.3003 – -0.3003 | 0.00 | 0.0% | 151.33K | -53.4% | 1 |
| Current year | -0.83757 | -0.86271 – -0.80 | 0.00 | 0.0% | 1.35M | -5.6% | 3 |
| Next year | -1.33 | -1.61 – -0.99 | -0.83757 | -58.6% | 596.88K | -55.9% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 25, 2024 | B of A Securities | Downgrade | Buy | Neutral |
| Nov 22, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Oct 24, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Oct 24, 2024 | UBS | Initiated | — | Buy |
| Oct 11, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Oct 1, 2024 | Wedbush | Initiated | — | Outperform |
| Sep 25, 2024 | Truist Securities | Initiated | — | Buy |
| Sep 10, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Sep 9, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Sep 6, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Sep 3, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Aug 16, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 13, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Jul 25, 2024 | B of A Securities | Initiated | — | Buy |
| Jun 25, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Jun 20, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Jun 18, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Jun 18, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Jun 14, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| May 16, 2024 | Jones Trading | Maintained | Buy | Buy |
| May 14, 2024 | RBC Capital | Initiated | — | Outperform |
| May 9, 2024 | Cantor Fitzgerald | Initiated | — | Overweight |
| Apr 9, 2024 | B. Riley Securities | Maintained | Buy | Buy |
| Apr 1, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Mar 19, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Jan 26, 2024 | B. Riley Securities | Initiated | — | Buy |
| Nov 15, 2023 | JonesTrading | Initiated | — | Buy |
| May 19, 2023 | Oppenheimer | Maintained | — | Outperform |